About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Breast Cancer Clinical Trials in Detroit | 437 Studies

Clinical Trials Breast CancerDetroit

Breast Cancer Clinical Trials in Detroit

Find 437 clinical trials for breast cancer near Detroit, Michigan. Connect with research centers in your area.

All Breast Cancer trials nationwide All trials in Detroit

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4Not applicable

Who can join

Healthy volunteers too

Showing 401-420 of 437 trials

CompletedPhase I Study of CDX-1307, hCG-B Vaccine, for Patients With Incurable, Locally Advanced or Metastatic Breast, Colorectal, Pancreatic, Bladder or Ovarian CancerThis research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer.NCT00648102·Detroit, Michigan and 2 others CompletedA Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or…NCT01602380·Modesto, California and 117 others

Breast Cancer Trials in Other Cities

New York Los Angeles Chicago Houston Phoenix Philadelphia

Data from ClinicalTrials.govTerms

CompletedStudy Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerThis is a randomized, Phase II, double-blind, multicenter, placebo-controlled trial designed to preliminarily estimate the efficacy and evaluate the safety and tolerability of…NCT01186991·Bakersfield, California and 52 others

CompletedContinued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast CancerClinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen.NCT00320710·Anchorage, Alaska and 91 others

RecruitingStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe…NCT05633654·Birmingham, Alabama and 377 others

RecruitingShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus TrastuzumabThis phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive…NCT06876714·Phoenix, Arizona and 701 others

Active not recruitingTamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast CancerThis randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby…NCT02311933·Mobile, Alabama and 558 others

Active not recruitingA Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced DiseaseThe study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the…NCT04711252·Mobile, Alabama and 262 others

CompletedDS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]This study will compare DS 8201a to standard treatment. Participants must have HER2 breast cancer that has been treated before.NCT03523585·Chandler, Arizona and 226 others

Active not recruitingEndocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer PatientsThis study evaluates endocrine therapy-induced alopecia among postmenopausal and premenopausal female patients with breast cancer.NCT05612100·Albert Lea, Minnesota and 22 others

Active not recruitingAn Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer…NCT05952557·Dothan, Alabama and 660 others

TerminatedStudy Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast CancerThis is a phase 2 study of bosutinib administered in combination with letrozole versus letrozole alone in post-menopausal women with breast cancer. This is a 2-part study.NCT00880009·Whittier, California and 10 others

Active not recruitingA Study of PARG Inhibitor IDE161 in Participants With Advanced Solid TumorsThe purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.NCT05787587·Phoenix, Arizona and 26 others

Active not recruitingTesting MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast CancerThis randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer.NCT02954874·Birmingham, Alabama and 918 others

CompletedS9630, Medroxyprogesterone in Treating Women With Breast CancerRATIONALE: It is not yet known whether medroxyprogesterone is effective in preventing endometrial disorder in patients with breast cancer who are taking tamoxifen.NCT00002920·Mobile, Alabama and 121 others

Active not recruitingA Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the…NCT06065748·Daphne, Alabama and 310 others

RecruitingA Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination TherapyThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus…NCT05646862·Greenbrae, California and 209 others

CompletedA Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast CancerThis two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in…NCT01966471·Scottsdale, Arizona and 294 others

CompletedA Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of LapatinibThis study will assess alternative formulations of lapatinib for relative bioavailability and bioequivalence (BE) with the current commercial formulation (reference).NCT00996762·Scottsdale, Arizona and 8 others

CompletedA Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesThe purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01949 when given in combination with immune therapies in participants with advanced or…NCT03241173·Birmingham, Alabama and 14 others

PreviousPage 21 of 22Next

Other Conditions in Detroit

Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma